Zydus Hospira Oncology gets EIR for its Ahmedabad facility

Published On 2018-07-15 04:45 GMT | Update On 2018-07-15 04:45 GMT

New Delhi: Drug firm Zydus Cadila said Zydus Hospira Oncology, a JV between the company and Hospira Inc, has received Establishment Inspection Report (EIR) from the US health regulator for its Ahemdabad manufacturing facility.

The EIR from the United States Food and Drug Administration (USFDA) has concluded that the inspection is closed but has also said that the inspection classification of this facility is 'voluntary action indicated' (VAI).

According to the USFDA, VAI means that though objectionable conditions were found and documented, but the agency is not prepared to take or recommend regulatory action.

Zydus Hospira Oncology is a 50:50 joint venture company between Zydus Cadila and Hospira Inc USA (now part of Pfizer Group), Zydus Cadila said.

The manufacturing plant had completed the USFDA audit from April 5 to April 12, 2018, it added.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Hospira Oncology gets EIR for its Ahmedabad facility

Similar News